株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオマーカー分析における技術革新

Innovations in Biomarker Analytics

発行 Frost & Sullivan 商品コード 914934
出版日 ページ情報 英文 49 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
バイオマーカー分析における技術革新 Innovations in Biomarker Analytics
出版日: 2019年10月14日 ページ情報: 英文 49 Pages
概要

ここ数年、バイオマーカー分析は大きく発展し、薬剤開発プロセスの加速に寄与しています。AIに基づく技術の使用も、バイオマーカー分析の効率を上げています。

当レポートでは、バイオマーカー分析における技術革新動向について調査し、市場の動向と課題、業界連携動向などについてまとめています。

第1章 エグゼクティブサマリー

第2章 バイオマーカーと分析:イントロダクション

  • 薬剤開発プロセスにおけるバイオマーカーとその役割
  • バイオマーカー特定に貢献する重要データ作成プロセス
  • バイオマーカーは薬剤開発プロセスにおいて多様な使用法がある

第3章 バイオマーカーと大量データ

  • データプロセシングとパターン認識
  • 考えうるデータソース
  • 影響因子
  • 重要側面とプロセス

第4章 バイオマーカー分析でのAI使用に影響を及ぼす促進因子と課題

  • 影響因子
  • 短期的、長期的影響

第5章 バイオマーカー分析と薬剤開発のためのAIに対する資金調達と投資

世界的なライフサイエンスへの投資拡大

第6章 様々な業界連携のタイムライン

第7章 業界動向

  • 企業プロファイル:NuMediiと Recursion Pharmaceuticals
  • 企業プロファイル:GNS Healthcare と Insilico Medicine
  • 企業プロファイル:Standigm と twoXAR
  • 企業プロファイル:ExScientia と BioXcel Therapeutics
  • 企業プロファイル:Benevolent AI と Berg Health

第8章 成長の機会

第9章 付録

目次
Product Code: D8DA

Tracking the Market Landscape of Companies Striving to Derive Actionable Insights from the Data Deluge through the incorporation of Artificial Intelligence

Biomarker Analytics has always been one of the most in-demand branches of science relevant to the process of drug discovery and development in the Pharmaceutical Industry. Over the years several advances have been made in the area of biomarker analytics with the aim to accelerate the drug development process. The use of AI-based technology can increase the efficiency of biomarker analytics.

With the huge data deluges generated through various platforms such as omics, diagnostics etc., machine learning and deep learning techniques are slowly proving to be highly effective in sifting through data and identifying critical biomarkers through pattern recognition. This global research service provides extensive information about the industry trends, market landscape, latest technological advances and AI-based developments in the biomarker analytics industry that hold immense potential in accelerating the process of drug development in the pharmaceutical industry.

Table of Contents

1.0 Executive Summary

  • 1.1 Research Objectives
  • 1.2 Research Methodology
  • 1.3 Key Predictions: Biomarker Analytics

2.0 Biomarkers and Analytics--Introduction

  • 2.1 Biomarkers and Their Role in Drug Development Process
  • 2.2 Critical Data Generation Processes Contributing to Biomarker Identification
  • 2.3 Biomarkers Have Multiple Uses in Drug Development Process

3.0 Biomarkers and Data Deluge

  • 3.1 Data Processing and Pattern Recognition Key to Biomarker Analytics
  • 3.2 Possible Data Sources for Biomarker Analytics
  • 3.3 Factors Affecting Use of AI in Biomarker Analytics
  • 3.4 Key Aspects and Processes for The Use of AI for Biomarker Analytics

4.0 Drivers and Challenges Affecting the Use of AI for Biomarker Analytics

  • 4.1 Factors Impacting The Use of AI for Biomarker Analytics
  • 4.2 AI Will Have Both Short-Term and Long-Term Effect on Biomarker Analytics

5.0 Funding and Investments in AI for Biomarker Analytics and Drug Development

  • 5.1 Increasing Global Life Science Investments in AI startups Focused on Drug Development
  • 5.2 Recursion Pharmaceuticals Has Pulled in The Highest Individual Series Funding Round for AI-Based Drug Discovery
  • 5.3 Benevolent AI Is Currently The Highest Funded AI-based Drug Discovery Venture

6.0 Timeline of Various Industrial Collaborations

  • 6.1 Numerate, NuMedii, and ExScientia Were Some of The Early Movers
  • 6.2 Benevolent AI and Insilico Medicine Were The Trailblazers
  • 6.3 Multiple Research Collaborations Were Agreed in 2016/2017
  • 6.4 GNS Healthcare Reported The Highest Number of Industrial Collaborations in 2017
  • 6.5 Year 2018 Marked The Entry of Multiple AI-based Startups Focused on Biomarker Analytics and Drug Discovery
  • 6.6 Industrial Collaborations Continue to Be A Global Phenomenon Rather Than Regional Ones
  • 6.7 Atomwise Reported The Highest Potential Industrial Collaboration Deal in 2019
  • 6.8 Global Trends Position North America and Europe as Leaders in Applying AI for Biomarkers and Drug Development Process

7.0 Industry Landscape of selected companies

  • 7.1 Company Profile: NuMedii & Recursion Pharmaceuticals
  • 7.2 Company Profile: GNS Healthcare & Insilico Medicine
  • 7.3 Company Profile: Standigm & twoXAR
  • 7.4 Company Profile: ExScientia & BioXcel Therapeutics
  • 7.5 Company Profile: Benevolent AI & Berg Health

8.0 Growth Opportunities

  • 8.1 Growth Opportunity 1: Adoption of AI by The Pharmaceutical Industry for Biomarker Analytics
  • 8Industrial Collaborations Can Lead to Increased Access to Proprietary Databases
  • 8Building More Effective Algorithms and Eliminating Data Bias

9.0 Appendix

  • 9.1 Key Contacts
  • 9.1 Key Contacts (continued)
  • 9.1 Key Contacts (continued)
  • Legal Disclaimer
Back to Top